• TScan entered an agreement with Cellares to evaluate automated clinical manufacturing of its lead TCR-T candidate, TSC-101.
• Assessment will cover technical, operational fit of Cellares’ Cell Shuttle manufacturing platform, Cell Q automated quality-control release testing system.
• TSC-101 targets relapse prevention in AML, MDS patients undergoing allogeneic hematopoietic cell transplantation; uses healthy donor T cells for patient-specific product.
• Evaluation supports commercial readiness as TScan plans a pivotal TSC-101 trial start in Q2 2026.
• Automation focus aims to cut variability, labor needs, capacity constraints; improve scalability, manufacturing economics for potential commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606030919BIZWIRE_USPR_____20260603_BW703141) on June 03, 2026, and is solely responsible for the information contained therein.